Can You Take HYDROCODONE BITARTRATE AND ACETAMINOPHEN with Gabapentin?
A plain-English look at the major interaction between HYDROCODONE BITARTRATE AND ACETAMINOPHEN (Hydrocodone Bitartrate and Acetaminophen) and Gabapentin (Neurontin) — what it means, why it happens, and what to talk to your doctor or pharmacist about.
Taking HYDROCODONE BITARTRATE AND ACETAMINOPHEN (Hydrocodone Bitartrate and Acetaminophen) with Gabapentin (Neurontin) is a major drug interaction that should be avoided. Respiratory depression, excessive sedation, overdose. Additive CNS depression. Gabapentinoids potentiate opioid-induced respiratory depression even at therapeutic doses.
Not sure about your specific combination? Check it in the Drug Interaction Checker →
Key Takeaways
- Interaction severity: Major
- Risk: Respiratory depression, excessive sedation, overdose.
- Mechanism: Additive CNS depression. Gabapentinoids potentiate opioid-induced respiratory depression even at therapeutic doses.
- HYDROCODONE BITARTRATE AND ACETAMINOPHEN: S8 in Australia, high risk
- Gabapentin: S4 in Australia, moderate risk
- Claims action: Flag for immediate prescriber review. Document intervention in claim file.
HYDROCODONE BITARTRATE AND ACETAMINOPHEN vs Gabapentin at a Glance
| Property | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | Gabapentin |
|---|---|---|
| Brand names | Hydrocodone Bitartrate and Acetaminophen | Neurontin, Nupentin 300, Gabapentin Sandoz |
| Drug class | opioid | gabapentinoid |
| Risk level | high | moderate |
| TGA Schedule (AU) | S8 | S4 |
Why Is This Combination Dangerous?
Additive CNS depression. Gabapentinoids potentiate opioid-induced respiratory depression even at therapeutic doses.
Regulatory Guidance by Jurisdiction
Australia TGA / SIRA / WorkSafe
The TGA and Australian Medicines Handbook classify this as a major drug interaction requiring immediate intervention.
The TGA has issued safety communications about the risk of respiratory depression when gabapentinoids are combined with opioids. WorkSafe Victoria Drugs of Dependence Guidelines require monitoring for this combination.
United Kingdom NICE / MHRA / FPM
The MHRA has issued Drug Safety Updates warning about the risk of respiratory depression and death when gabapentinoids are combined with opioids. NICE CG173 (Neuropathic Pain) recommends gabapentinoids as monotherapy, not in combination with opioids.
United States FDA / CDC / State WC
The FDA has added warnings to gabapentinoid labels about serious breathing difficulties when taken with opioids. The CDC opioid guidelines recommend caution with concurrent CNS depressant use. Some state formularies require prior authorization for this combination.
What Claims Professionals Should Do
- Flag immediately as a high-risk prescribing pattern in the claim file
- Request urgent prescriber review with documented clinical justification for the combination
- Consider an independent medical examination if the prescriber cannot provide adequate justification
- Assess work capacity impact as the combination significantly increases sedation and impairment risk
- Document all interventions for audit trail and compliance purposes
- Check Reasonable and Necessary status for both medications against the compensable injury
Check this medication against your full medication list
Check all interactions for HYDROCODONE BITARTRATE AND ACETAMINOPHEN and Gabapentin across your claimant's full medication list.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Related Resources
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.